A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

Slides:

Advertisements

Similar presentations

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Advertisements

PLUS.

Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.

Independent variables (baseline) Loge (HOMA-IR) b P

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Nat. Rev. Nephrol. doi: /nrneph

Volume 83, Issue 5, Pages (May 2013)

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Volume 83, Issue 5, Pages (May 2013)

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Effect of 11-day oral administration of vehicle (n = 4) or 6-day oral administration of enalapril 10 mg/kg per day (n = 19), followed by 5-day oral administration.

Decreased P-IR and total FOXO1 levels in an HFS diet.

Cyp8b1−/− mice have an altered circulating bile acid pool.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

Plasma angiopoietin-like protein 4 (ANGPTL4) in healthy controls (Controls), patients with metabolic syndrome without (MetS−I) and with low-grade inflammation.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Odds of incident diabetes by OGTT insulin patterns according to subjects characterized by presence or absence of IGT or dichotomized at the median value.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

IRS-1 and -2 expression in four mesangial cell lines from different D-NOD (A and B) and ND-NOD (C and D) mice. IRS-1 and -2 expression in four mesangial.

Plasma levels of GLP-1 are increased in patients with critical illness and correlate with disease severity. Plasma levels of GLP-1 are increased in patients.

Unlabeled and tracer glucocorticoids in plasma from arterialized samples and veins draining skeletal muscle and subcutaneous adipose tissue. Unlabeled.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

Intraperitoneal (IP) and intravenous (IV) milk fat inhibits leptin transport. Intraperitoneal (IP) and intravenous (IV) milk fat inhibits leptin transport.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Linearity of the relationships between spectral abundance factors observed when 30 and 120 μg protein were analyzed, as described in research design and.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

Expression of IRS2 ameliorates the effects of ATF3 in cultured β-cells

Mean plasma concentrations of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis (duration depicted by box.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

GLP-1 and gastrin combination therapy induces immunoregulatory cell activity in NOD mice. GLP-1 and gastrin combination therapy induces immunoregulatory.

Intracerebroventricular (ICV) insulin infusion increases TG secretion.

Sympathetic denervation decreases VLDL-TG secretion in the fasted state. Sympathetic denervation decreases VLDL-TG secretion in the fasted state. A: Plasma.

Glucose stimulates GLP-1 secretion from the perfused rat intestine by a dose- and absorption-dependent manner. Glucose stimulates GLP-1 secretion from.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

Baseline and follow-up values for HbA1c, WBISI, IGI, and ODI in NGT subjects divided according to development of IGT at follow-up (progressors [dark green.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Average percent change in serum leptin and soluble leptin receptor (sOB-R) levels in response to rhLeptin administration at a low dose (0.01 mg/kg) (n.

Lipoprotein lipase is decreased in skeletal muscle of young, lean IR offspring of T2D parents. Lipoprotein lipase is decreased in skeletal muscle of young,

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Bubble graph representing the relationship between the difference in estimated fat mass and the difference in plasma NEFA concentration in 43 independent.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effects of GIP and GLP-1 infusion on MR-proANP levels.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Correlations between leptin DNA methylation and 2-h post-OGTT glucose levels, within the IGT group (A and B), leptin DNA methylation and mRNA levels (C.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Results supporting the validity of TEF as a descriptor of posttransplant β-cell secretion. Results supporting the validity of TEF as a descriptor of posttransplant.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

GM-CSF is required for CA-MSC–induced tumor metastasis.

The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Presentation transcript:

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs A and B: Plasma levels of IR-GIP and xenin-25 during GGIs. Subjects with NGT were administered GGIs with a primed-continuous intravenous infusion of GIP alone, xenin-25 (Xen) alone, or the combination of GIP plus xenin-25. A and B: Plasma levels of IR-GIP and xenin-25 during GGIs. Subjects with NGT were administered GGIs with a primed-continuous intravenous infusion of GIP alone, xenin-25 (Xen) alone, or the combination of GIP plus xenin-25. IR peptide levels (group average ± SEM) in subjects with IGT and T2DM were similar to those shown for subjects with NGT. Burton M. Wice et al. Diabetes 2012;61:1793-1800 ©2012 by American Diabetes Association